The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

dyax.com

Founded Year

1989

Stage

Acq - P2P | Acquired

Total Raised

$48.8M

Valuation

$0000 

About Dyax

Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. Dyax also leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents.

Dyax Headquarter Location

55 Network Drive

Burlington, Massachusetts, 01803,

United States

617-225-2500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Dyax

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Dyax is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Dyax Patents

Dyax has filed 163 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Coagulation system
  • G protein coupled receptors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/26/2018

4/12/2022

Immunology, Immune system, Monoclonal antibodies, Protein domains, Clusters of differentiation

Grant

Application Date

11/26/2018

Grant Date

4/12/2022

Title

Related Topics

Immunology, Immune system, Monoclonal antibodies, Protein domains, Clusters of differentiation

Status

Grant

Latest Dyax News

Pulmatrix Strengthens Board of Directors with Appointment of Todd Bazemore

Sep 29, 2020

News provided by Share this article LEXINGTON, Mass., Sept. 29, 2020 /PRNewswire/ --  Pulmatrix, Inc. (NASDAQ: PULM ), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Todd Bazemore, a biopharmaceutical executive with significant experience in respiratory diseases, rare diseases, business development, and capital markets, to its Board of Directors, effective October 1, 2020. "I believe that Todd will be a great addition to our Board of Directors," said Ted Read, Chief Executive Officer of Pulmatrix. "He brings expertise in respiratory disease, including asthma and COPD, as well as significant rare disease experience while with Dyax and Santhera. Coupled with capital markets experience and an extensive track record in business development with acquisitions and transformative deals, Todd is a great addition to the Board. We look forward to his strategic guidance as we advance our mission to develop inhaled therapies in respiratory diseases and other diseases of significant unmet need. "   Mr. Bazemore is a biopharmaceutical executive with more than 25 years of experience spanning from ultra-rare orphan diseases to large primary care conditions. He is currently the Chief Operating Officer of Kala Pharmaceuticals, a company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Prior to joining Kala Pharmaceuticals in 2017, Mr. Bazemore served as Executive Vice President and Chief Operating Officer of Santhera Pharmaceuticals (USA), Inc. Prior to joining Santhera U.S., he served as Executive Vice President and Chief Commercial Officer of Dyax Corp. before its acquisition by Shire Plc in January of 2016. Prior to joining Dyax, Mr. Bazemore was at Sunovion Pharmaceuticals, Inc. (previously Sepracor Inc., prior to its acquisition by Sumitomo Dainippon Pharma Co., Ltd), where he served in several roles of increasing responsibility, including Vice President of the Respiratory Business Unit. "I'm excited to have the opportunity to work with Ted and the leadership team as they advance the current respiratory programs and to leverage the iSPERSE™ platform with the goal of growing the company's pipeline," said Mr. Bazemore. About Pulmatrix              Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. FORWARD-LOOKING STATEMENTS Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements of historical fact, and may be identified by words such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that", "may," "plans," "seeks," "projects," "targets," and "would," and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to,  the impact of the novel coronavirus (COVID-19) on the Company's ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on the Company's ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates, including the failure to maintain our collaboration with Cipla Technologies, LLC; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the SEC, including its annual report on Form 10-K filed with the Securities and Exchange Commission on March 26, 2020 as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Investor Contact

  • When was Dyax founded?

    Dyax was founded in 1989.

  • Where is Dyax's headquarters?

    Dyax's headquarters is located at 55 Network Drive, Burlington.

  • What is Dyax's latest funding round?

    Dyax's latest funding round is Acq - P2P.

  • How much did Dyax raise?

    Dyax raised a total of $48.8M.

  • Who are the investors of Dyax?

    Investors of Dyax include Shire, Alta Partners, Tekla Capital Management, ING, Genzyme and 8 more.

  • Who are Dyax's competitors?

    Competitors of Dyax include Oligomerix, Vernalis, LeadScope, Vitatex, Array Biopharma, NGM Biopharmaceuticals, Marinomed Biotech, ChemoCentryx, AmideBio, Zymeworks and 17 more.

You May Also Like

E
Escientia

is a contract research organization that collaborates with R&D departments of biotechnology and biopharmaceutical companies to discover and develop new medicines. The company also engages in its own drug discovery agenda to develop treatments of treat tropical diseases such as malaria.

C
Chroma Therapeutics

Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.

E
Emiliem

Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

D
Dialectica srl

Dialectica offers Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases. The mission of Dialectica is to add value to the link between research and pharmaceutical and biotechnology companies that are active in the discovery of therapeutics for brain diseases. Dialectica develops and optimize Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases.

Oligomerix Logo
Oligomerix

Oligomerix is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity. The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center.

Oceanit Logo
Oceanit

Oceanit creates solutions through engineering consulting in civil, coastal, and environmental engineering; information systems consulting; management consulting, including Design Thinking and scientific research.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.